Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

McMaster University

$120,000.00

Group 2 Innate Lymphoid Cells in Severe Asthma: Investigation of Mechanisms of Activation and Plasticity.

EF 2024-25

Résumé
Asthma affects 350 million people globally. It is treated with steroids that reduce airway swelling and mucus production, making breathing easier. However, 10% of patients with severe asthma (SA) continue to have breathing difficulties despite maximal medications resulting in hospitalization with significant personal and socioeconomic impacts. This cost the Canadian healthcare system $2.1 billion in 2016 and is projected to double by 2030. Newly licensed antibody treatments are effective but are only targeted for a sub-group of SA with increased eosinophils, a specific inflammatory cell in the lungs. SA patients with elevated airway neutrophils do not respond to these treatments, are prone to frequent worsening of symptoms, revealing a pressing clinical need. Investigating immunological mechanisms in SA who develop neutrophilic inflammation will provide new treatment targets for difficult-to-treat asthma. My project will study novel cells termed innate lymphoid cells (ILC) that are tissue-resident and produce pro-inflammatory factors. A sub-group, group 2 ILC (ILC2), play a role in asthma, allergies, and recruiting eosinophils, while ILC3 respond to infections and recruit neutrophils. We have found that increased numbers of activated ILC2 in the airways of eosinophilic SA while ILC3 are increased in SA with neutrophilic inflammation. We found that ILC2 can transform into ILC3-like cells, that secrete factors similar to ILC3 that attract neutrophils. My project aims to determine what mechanisms activate or stimulate ILC2 to transform to ILC3-like during asthma exacerbations. By following asthma patients when stable and during a flare-up, we will assess airway changes in (i) ILC cells relative to other immune cells including T cells, (ii) mediators of changing ILC2 within the airways. This will provide important information about drivers of ILC activity in asthma, effects on neutrophilia and potential testable targets for drugs to treat uncontrolled asthma.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
518236
Name
Emami Fard Nahal
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Group 2 Innate Lymphoid Cells in Severe Asthma: Investigation of Mechanisms of Activation and Plasticity.
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Asthma; Asthma Exacerbations; Cell Activation And Plasticity; Cytokines; Flow Cytometry; Inflammatory Phenotypes Of Asthma; Innate Lymphoid Cells; Neuro-Immune Axis Of Inflammation; Single Cell Rna Sequencing
Abstract
Asthma affects 350 million people globally. It is treated with steroids that reduce airway swelling and mucus production, making breathing easier. However, 10% of patients with severe asthma (SA) continue to have breathing difficulties despite maximal medications resulting in hospitalization with significant personal and socioeconomic impacts. This cost the Canadian healthcare system $2.1 billion in 2016 and is projected to double by 2030. Newly licensed antibody treatments are effective but are only targeted for a sub-group of SA with increased eosinophils, a specific inflammatory cell in the lungs. SA patients with elevated airway neutrophils do not respond to these treatments, are prone to frequent worsening of symptoms, revealing a pressing clinical need. Investigating immunological mechanisms in SA who develop neutrophilic inflammation will provide new treatment targets for difficult-to-treat asthma. My project will study novel cells termed innate lymphoid cells (ILC) that are tissue-resident and produce pro-inflammatory factors. A sub-group, group 2 ILC (ILC2), play a role in asthma, allergies, and recruiting eosinophils, while ILC3 respond to infections and recruit neutrophils. We have found that increased numbers of activated ILC2 in the airways of eosinophilic SA while ILC3 are increased in SA with neutrophilic inflammation. We found that ILC2 can transform into ILC3-like cells, that secrete factors similar to ILC3 that attract neutrophils. My project aims to determine what mechanisms activate or stimulate ILC2 to transform to ILC3-like during asthma exacerbations. By following asthma patients when stable and during a flare-up, we will assess airway changes in (i) ILC cells relative to other immune cells including T cells, (ii) mediators of changing ILC2 within the airways. This will provide important information about drivers of ILC activity in asthma, effects on neutrophilia and potential testable targets for drugs to treat uncontrolled asthma.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Emami Fard, Nahal
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~